vs
Side-by-side financial comparison of GCM Grosvenor Inc. (GCMG) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
Pacira BioSciences, Inc. is the larger business by last-quarter revenue ($177.4M vs $177.1M, roughly 1.0× GCM Grosvenor Inc.). GCM Grosvenor Inc. runs the higher net margin — 32.8% vs 1.6%, a 31.2% gap on every dollar of revenue. On growth, GCM Grosvenor Inc. posted the faster year-over-year revenue change (7.2% vs 5.0%). Over the past eight quarters, GCM Grosvenor Inc.'s revenue compounded faster (27.5% CAGR vs -0.2%).
GCM Grosvenor is an American alternative asset management firm, with approximately $76 billion in assets under management and approximately 530 professionals as of 2023.
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
GCMG vs PCRX — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $177.1M | $177.4M |
| Net Profit | $58.2M | $2.9M |
| Gross Margin | — | — |
| Operating Margin | 30.9% | 3.9% |
| Net Margin | 32.8% | 1.6% |
| Revenue YoY | 7.2% | 5.0% |
| Net Profit YoY | 149.2% | — |
| EPS (diluted) | $0.23 | $0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $177.4M | ||
| Q4 25 | $177.1M | $196.9M | ||
| Q3 25 | $135.0M | $179.5M | ||
| Q2 25 | $119.7M | $181.1M | ||
| Q1 25 | $125.8M | $168.9M | ||
| Q4 24 | $165.3M | $187.3M | ||
| Q3 24 | $122.9M | $168.6M | ||
| Q2 24 | $117.0M | $178.0M |
| Q1 26 | — | $2.9M | ||
| Q4 25 | $58.2M | — | ||
| Q3 25 | $10.5M | $5.4M | ||
| Q2 25 | $15.4M | $-4.8M | ||
| Q1 25 | $463.0K | $4.8M | ||
| Q4 24 | $7.6M | — | ||
| Q3 24 | $4.2M | $-143.5M | ||
| Q2 24 | $4.8M | $18.9M |
| Q1 26 | — | — | ||
| Q4 25 | — | 79.5% | ||
| Q3 25 | — | 80.9% | ||
| Q2 25 | — | 77.4% | ||
| Q1 25 | — | 79.7% | ||
| Q4 24 | — | 78.7% | ||
| Q3 24 | — | 76.9% | ||
| Q2 24 | — | 75.1% |
| Q1 26 | — | 3.9% | ||
| Q4 25 | 30.9% | 1.2% | ||
| Q3 25 | 32.7% | 3.5% | ||
| Q2 25 | 16.1% | 4.7% | ||
| Q1 25 | 12.2% | 1.2% | ||
| Q4 24 | 26.4% | 13.2% | ||
| Q3 24 | 20.3% | -82.8% | ||
| Q2 24 | 17.8% | 15.9% |
| Q1 26 | — | 1.6% | ||
| Q4 25 | 32.8% | — | ||
| Q3 25 | 7.8% | 3.0% | ||
| Q2 25 | 12.9% | -2.7% | ||
| Q1 25 | 0.4% | 2.8% | ||
| Q4 24 | 4.6% | — | ||
| Q3 24 | 3.4% | -85.1% | ||
| Q2 24 | 4.1% | 10.6% |
| Q1 26 | — | $0.07 | ||
| Q4 25 | $0.23 | $0.05 | ||
| Q3 25 | $0.16 | $0.12 | ||
| Q2 25 | $0.05 | $-0.11 | ||
| Q1 25 | $-0.02 | $0.10 | ||
| Q4 24 | $0.09 | $0.38 | ||
| Q3 24 | $0.03 | $-3.11 | ||
| Q2 24 | $0.04 | $0.39 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $242.1M | $144.3M |
| Total DebtLower is stronger | $428.4M | — |
| Stockholders' EquityBook value | $27.0M | $653.9M |
| Total Assets | $813.8M | $1.2B |
| Debt / EquityLower = less leverage | 15.87× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $144.3M | ||
| Q4 25 | $242.1M | $238.4M | ||
| Q3 25 | $182.7M | $246.3M | ||
| Q2 25 | $136.3M | $445.9M | ||
| Q1 25 | $94.5M | $493.6M | ||
| Q4 24 | $89.5M | $484.6M | ||
| Q3 24 | $98.4M | $453.8M | ||
| Q2 24 | $73.9M | $404.2M |
| Q1 26 | — | — | ||
| Q4 25 | $428.4M | $372.2M | ||
| Q3 25 | $429.3M | $376.7M | ||
| Q2 25 | $430.2M | $580.5M | ||
| Q1 25 | $431.1M | $583.4M | ||
| Q4 24 | $432.0M | $585.3M | ||
| Q3 24 | $432.9M | — | ||
| Q2 24 | $433.8M | — |
| Q1 26 | — | $653.9M | ||
| Q4 25 | $27.0M | $693.1M | ||
| Q3 25 | $-7.4M | $727.2M | ||
| Q2 25 | $-12.3M | $757.8M | ||
| Q1 25 | $-28.3M | $798.5M | ||
| Q4 24 | $-27.6M | $778.3M | ||
| Q3 24 | $-31.9M | $749.6M | ||
| Q2 24 | $-28.5M | $879.3M |
| Q1 26 | — | $1.2B | ||
| Q4 25 | $813.8M | $1.3B | ||
| Q3 25 | $685.9M | $1.3B | ||
| Q2 25 | $636.9M | $1.5B | ||
| Q1 25 | $579.8M | $1.6B | ||
| Q4 24 | $612.7M | $1.6B | ||
| Q3 24 | $575.0M | $1.5B | ||
| Q2 24 | $543.9M | $1.6B |
| Q1 26 | — | — | ||
| Q4 25 | 15.87× | 0.54× | ||
| Q3 25 | — | 0.52× | ||
| Q2 25 | — | 0.77× | ||
| Q1 25 | — | 0.73× | ||
| Q4 24 | — | 0.75× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $183.5M | — |
| Free Cash FlowOCF − Capex | $175.0M | — |
| FCF MarginFCF / Revenue | 98.8% | — |
| Capex IntensityCapex / Revenue | 4.8% | — |
| Cash ConversionOCF / Net Profit | 3.16× | — |
| TTM Free Cash FlowTrailing 4 quarters | $326.2M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $183.5M | $43.7M | ||
| Q3 25 | $79.8M | $60.8M | ||
| Q2 25 | $42.0M | $12.0M | ||
| Q1 25 | $33.3M | $35.5M | ||
| Q4 24 | $148.8M | $33.1M | ||
| Q3 24 | $69.0M | $53.9M | ||
| Q2 24 | $17.5M | $53.2M |
| Q1 26 | — | — | ||
| Q4 25 | $175.0M | $43.5M | ||
| Q3 25 | $78.3M | $57.0M | ||
| Q2 25 | $40.8M | $9.3M | ||
| Q1 25 | $32.1M | $26.9M | ||
| Q4 24 | $132.0M | $31.0M | ||
| Q3 24 | $62.2M | $49.8M | ||
| Q2 24 | $12.8M | $51.6M |
| Q1 26 | — | — | ||
| Q4 25 | 98.8% | 22.1% | ||
| Q3 25 | 58.0% | 31.7% | ||
| Q2 25 | 34.1% | 5.1% | ||
| Q1 25 | 25.5% | 15.9% | ||
| Q4 24 | 79.9% | 16.6% | ||
| Q3 24 | 50.6% | 29.6% | ||
| Q2 24 | 10.9% | 29.0% |
| Q1 26 | — | — | ||
| Q4 25 | 4.8% | 0.1% | ||
| Q3 25 | 1.1% | 2.2% | ||
| Q2 25 | 1.0% | 1.5% | ||
| Q1 25 | 0.9% | 5.1% | ||
| Q4 24 | 10.1% | 1.1% | ||
| Q3 24 | 5.5% | 2.4% | ||
| Q2 24 | 4.0% | 0.9% |
| Q1 26 | — | — | ||
| Q4 25 | 3.16× | — | ||
| Q3 25 | 7.61× | 11.20× | ||
| Q2 25 | 2.72× | — | ||
| Q1 25 | 71.84× | 7.37× | ||
| Q4 24 | 19.54× | — | ||
| Q3 24 | 16.60× | — | ||
| Q2 24 | 3.64× | 2.82× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GCMG
| Asset Management1 | $108.6M | 61% |
| Management Service Incentive Performance Fees | $61.7M | 35% |
| Management Service Incentive Carried Interest | $5.1M | 3% |
| Service Other | $1.8M | 1% |
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
